Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Immediate and Substantial Dilution (new) — The prospectus states investors will incur immediate and substantial dilution, but the per-share amount is not yet disclosed, and the offering price is expected to be substantially above net tangible book value.
- Large Option and Warrant Overhang Below Market Price (new) — Outstanding options and warrants have exercise prices far below the last sale price, creating significant potential dilution if exercised.
- Series A Preferred Stock Conversion (new) — The Series A Preferred Stock is convertible into a large number of common shares, which would significantly dilute existing holders upon conversion.
Spyre Therapeutics files preliminary prospectus for common stock offering; terms not yet set, last sale $93.19
Filed October 5, 2026 · ~2 min read
Key Changes
-
high
Offering size and price are not yet determined; the prospectus supplement leaves share count and public offering price blank.
The Offering verify on EDGAR → -
high
Net proceeds will fund pipeline advancement across Gastroenterology, Rheumatology, and Dermatology, including a new program to advance SPY072 into late-stage development for hidradenitis suppurativa.
Use of Proceeds verify on EDGAR → -
high
Investors will incur immediate and substantial dilution, but the per-share dilution amount is not yet disclosed.
Dilution verify on EDGAR →
6 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade SYRE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Oct 5, 2026 · How we verify